12:00 AM
 | 
Feb 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Romosozumab: Development discontinued

Amgen and partner UCB discontinued development of romosozumab to improve fracture healing after top-line data from a double-blind, international Phase II trial showed that the compound missed the primary endpoint of improving time to radiographic healing at 52 weeks vs. placebo. The trial enrolled about 400 patients with a fresh unilateral tibial diaphyseal fracture who underwent a definitive fracture fixation...

Read the full 279 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >